Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Trump Media and Technology Group Corp (DJT) vs Enveric Biosciences Inc (ENVB) Price & Performance

Trump Media and Technology Group CorpTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Trump Media and Technology Group Corp vs Enveric Biosciences Inc — how do they compare? Trump Media and Technology Group Corp trades at $8.37 (market cap $2.48B), while Enveric Biosciences Inc trades at $1.59 (market cap $6.20M). The key difference: Trump Media and Technology Group Corp is far larger — about 400× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.

DJTENVB
Market Cap
$2.48B$6.20M
Sector
MediaHealth
52-Week High
$18.50$17.40
52-Week Low
$7.06$1.27
Enterprise Value
$2.54B$1.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Trump Media and Technology Group Corp

DJT stock trades at $8.38, down 10.81% in the last 24 hours, reflecting a bearish technical signal. The company reported Q2 2026 revenue of $1.67 million, up 89% year-over-year, but net losses widened to $238.1 million due to digital asset declines. The price-to-sales ratio of 547.62 indicates an extremely high valuation relative to minimal revenue, while negative profitability metrics and substantial cash burn persist.

The outlook remains highly speculative with significant risks from unsustainable losses and volatile digital asset holdings. Investment appeal is limited to high-risk tolerance given the lack of profitability and bearish analyst sentiment. Key catalysts include future revenue growth from new products like the Truth API, but current fundamentals do not support the valuation.

Enveric Biosciences Inc

ENVB trades at $1.59, up 3.25% today, with a bullish technical signal driven by moving averages. The company, a biotechnology firm developing neuroplastogenic therapeutics, reported significant earnings beats in all quarters of 2025, including a positive EPS of $0.85 in Q4 versus an expected loss. Recent news highlights progress with its lead candidate EB-003, including non-hallucinogenic profile confirmations and FDA guidance alignment, though financials show negative ROE and ROA with net income of -$8.77M in 2025.

The outlook is cautiously optimistic due to strong analyst support (75% buy ratings) and clinical advancements, but high financial losses and reliance on financing cash flow pose risks. Stock performance hinges on successful drug development milestones and future profitability, with current sentiment buoyed by technical strength and positive pipeline updates.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Trump Media and Technology Group Corp

Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.

Read more on DJT

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB